Search Results - "WILSHER, N"

Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene by SALE, S, VERSCHOYLE, R. D, BOOCOCK, D, JONES, D. J. L, WILSHER, N, RUPARELIA, K. C, POTTER, G. A, FARMER, P. B, STEWARD, W. P, GESCHER, A. J

“…Resveratrol (trans-3,5,4'-trihydroxystilbene) is a naturally occurring polyphenol with cancer chemopreventive properties in preclinical models of…”
Get full text

878 PRE-CLINICAL CHARACTERISATION OF A NOVEL DIRECT ACTING ANTIVIRAL AGENT WITH A NEW MODE OF ACTION by Wilsher, N, Saalau-Bethell, S, Woodhead, A, Millemaggi, A, Graham, B, Hamlett, C, Murray, C, Norton, D, Rees, D, Chiarparin, E, Willems, H, Lewis, J, Fazal, L, Carr, M, Hodder, M, Reader, M, Thompson, N, Pathuri, P, Rich, S, Hiscock, S, Martins, V, Sanders, M

Get full text

A validated liquid chromatographic–tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma by Martins, Vanessa, Asad, Yasmin, Wilsher, Nicola, Raynaud, Florence

“…A sensitive and selective LC–MS/MS method has been developed and validated for the quantification of abiraterone acetate and its metabolite, abiraterone (an…”
Get full text

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy by MCLAY, Lain M, HALLEY, Frank, FOSTER, Martyn, HELE, David, JAYYOSI, Zaid, KELLEY, Mike, MASLEN, Chris, MILLER, Glen, OULDELHKIM, Marie-Claude, PAGE, Kenneth, PHIPPS, Simon, POLLOCK, Kenneth, SOUNESS, John E, PORTER, Barry, RATCLIFFE, Andrew J, REDFORD, Elisabeth J, WEBBER, Stephen, SLATER, Bryan, THYBAUD, Veronique, WILSHER, Nicola, MCKENNA, Jeffrey, BENNING, Veronique, BIRRELL, Mark, BURTON, Brenda, BELVISI, Maria, COLLIS, Alan, CONSTAN, Alex

“…RPR132331, a 2-(2-dioxanyl)imidazole, was identified as an inhibitor of tumour necrosis factor (TNF)alpha release from lipopolysaccharide (LPS)-stimulated…”
Get full text

289 (PB277): Pulsatile induction of the p53 pathway by MDM2 antagonist ASTX295 shows an enhanced therapeutic index in vivo by Fazal, L., Biondo, A., Ahn, M., Bevan, L., Hearn, K., Howard, S., Jueliger, S., Chessari, G., Kucia-Tran, J., Shah, A., Sims, M., Wilsher, N., Keer, H., Organesian, A., Wedge, S., Thomas, H., Zhao, Y., Newell, D., Wallis, N., Courtin, A.

Get full text

Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models by Smyth, T., Brothwood, J., Fazal, L., Hearn, K., Hindley, C., Johnson, C., Jones, M., Kandola, N., Lyons, J., Martins, V., Miyadera, K., Muench, S., Munck, J., Nakatsuru, Y., Ochiiwa, H., Saini, H., Shah, A., Wagner, S., Wilsher, N., Wallis, N.

Get full text

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency by Collis, Alan J, Foster, Martyn L, Halley, Frank, Maslen, Christopher, McLay, Iain M, Page, Kenneth M, Redford, E.Jane, Souness, John E, Wilsher, Nicola E

“…Following the discovery of RPR200765, a series of pyrimidine analogues have been prepared as backups. Amongst them, RPR203494 was identified with a better in…”
Get full text

Identification of potent small molecule allosteric inhibitors of SHP2 by Hearn, K., Berdini, V., Chessari, G., Davies, T.G., Day, J.E.H., Hamlett, C., Hiscock, S., Martins, V., Muench, S., Nakatsuru, Y., Ochiiwa, H., Price, A., Rich, S., Shah, A., Shibata, Y., Shimamura, T., Smyth, T., Wallis, N.G., Wilsher, N.E., Johnson, C.N.

Get full text

The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models by Munck, J., Berdini, V., Courtin, A., East, C., Heightman, T., Hindley, C., Kucia-Tran, J., Lyons, J., Martins, V., Muench, S., Murray, C., Norton, D., O’Reilly, M., Reader, M., Rees, D., Rich, S., Thompson, N., Wilsher, N., Woolford, A., Wallis, N.

Get full text